Saturday, June 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Vaccine roll out could potentially extend out to years

Because of the slow and disjointed rollout of vaccinations, the Covid-19 pandemic could last seven more years if distribution continues at its current rate.

A gloomy calculation from Bloomberg shows it could take most of a decade using two-dose vaccines for herd immunity to be reached. Previous calculations by White House chief medical advisor Dr. Anthony Fauci claimed 70-85 percent of the population will need the vaccine in order to achieve herd immunity.

Currently, the US is on track for that mark to be reached by 2022. But serious distribution complications and lack of vaccines in other countries are far from that figure.

Source: Bloomberg

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!